“USPSTF would be nice to have, to be honest with you, but in the first six to twelve months, we're assuming that that's not gonna be in play, and we our plans are really based on our value proposition of lenacapavir.”

In context

“hen you think about IAS guidelines. We already have lenacapavir there prior to even approval, but usually, they wait for approval, and then we kinda go forward with trying to get medical updates through the through including USPSTF. We do believe though that despite this, we feel we're incredibly well-positioned because of the transformative nature of lenacapavir to build access across the different channels that and we're prepared to do that. And that's, again, gonna take a little bit of time over the next six to twelve months. But we feel that that would be in line with what we've seen in the past with other agents, including Descovy, and we're gonna be leveraging all the guidelines possible to make sure that there's a real value that's displayed for access to go as quickly as possible. USPSTF would be nice to have, to be honest with you, but in the first six to twelve months, we're assuming that that's not gonna be in play, and we our plans are really based on our value proposition of lenacapavir. Our next question comes from Geoff Meacham at Citigroup. Geoff, go ahead. Your line is open. Geoff Meacham: Oh, great. Afternoon, guys. Thanks so much for the question. I have one for, for Dietmar. So on the HIV treatment, opportunity and looking to your long-acting orals, I guess the question is, what's the gating factor for selecting the best phase three combo? And related to that, you know, while you haven't seen resistance with len, it really been an issue. Would it still make sense to have you know, in the treatment setting, a three-drug versus a two-drug combo just to mitigate the lower risk, of resistance? Thank you. Dietmar Berger: Thank you, Geoff, for the question. Right? That's really early in our development program here. I think the important piece is that we're looking for o”